Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 20;25(8):583-592.
doi: 10.3779/j.issn.1009-3419.2022.101.41.

[Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated Advanced Non-small Cell Lung Cancer]

[Article in Chinese]
Bowen Li  1 , Jianchao Xue  1 , Yadong Wang  1 , Zhicheng Huang  1 , Naixin Liang  1 , Shanqing Li  1
Affiliations
Review

[Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated Advanced Non-small Cell Lung Cancer]

[Article in Chinese]
Bowen Li et al. Zhongguo Fei Ai Za Zhi. .

Abstract
in English, Chinese

Lung cancer is one of the leading causes of cancer-related morbidity and mortality. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) have become the standard treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC). Unfortunately, drug resistance is inevitable in most cases. EGFR-TKI combined with angiogenesis inhibitors is a treatment scheme being explored to delay the therapeutic resistance, which is called "A+T treatment". Several clinical trials have demonstrated that the A+T treatment can improve the progression free survival (PFS) of the NSCLC patients. However, compared to EGFR-TKI monotherapy, the benefits of the A+T treatment based on different EGFR-TKIs, as well as its safety and exploration prospects are still unclear. Therefore, we reviewed the literature related to all three generations EGFR-TKIs combined with angiogenesis inhibitors, and summarized the mechanism, benefit, safety, optimal target population of A+T treatment. .

【中文题目：抗血管生成药物联合EGFR-TKI治疗EGFR突变晚期非小细胞肺癌的研究进展】 【中文摘要：肺癌是最常见、致死率最高的肿瘤性疾病之一，使用表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitor, EGRF-TKI）已经成为EGFR突变晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）的标准治疗方式。然而耐药事件的发生往往是不可避免的。EGFR-TKI联合抗血管生成药物（angiogenesis inhibitor）是目前一种正在探索的延缓耐药事件发生的治疗方案，被称为“A+T治疗”。多项临床试验已经证明A+T治疗相较于单药可以延长患者的无进展生存期（progression free survival, PFS）。然而，基于不同EGFR-TKI的A+T治疗相对于EGFR-TKI单药治疗所带来的获益程度、安全性和探索前景仍不明确。因此，我们回顾了第一、二、三代EGFR-TKI联合抗血管生成药物治疗的相关文献，总结了A+T治疗模式的增益机制、获益程度、安全性以及最佳的目标人群。 】 【中文关键词：肺肿瘤；表皮生长因子受体；抗血管生成药物；联合治疗】.

Keywords: Antiangiogenic drugs; Combined modality therapy; Epidermal growth factor receptor; Lung neoplasms.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Huang Z, Su W, Lu T, et al. First-line immune-checkpoint inhibitors in non-small cell lung cancer: current landscape and future progress. Front Pharmacol. 2020;11:578091. doi: 10.3389/fphar.2020.578091. - DOI - PMC - PubMed
    1. Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) Lung Cancer. 2019;137:113–122. doi: 10.1016/j.lungcan.2019.09.017. - DOI - PMC - PubMed
    1. Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52(Pt 1):103–109. doi: 10.1016/j.semcancer.2017.11.019. - DOI - PMC - PubMed
    1. Hsu WH, Yang JC, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29(suppl_1):i3–i9. doi: 10.1093/annonc/mdx702. - DOI - PubMed
    1. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S24–S31. doi: 10.1038/onc.2009.198. - DOI - PMC - PubMed

MeSH terms